2 results match your criteria: "11th Floor 3400 Civic Center Boulevard[Affiliation]"
Identifying Racial, Ethnic, and Socioeconomic Inequities in the Use of Novel P2Y12 Inhibitors After Percutaneous Coronary Intervention.
J Invasive Cardiol
March 2022
Hospital of the University of Pennsylvania Cardiovascular Medicine Division, Perelman Center, South Tower, 11th Floor 3400 Civic Center Boulevard, Philadelphia, PA, 19104 USA.
Article Synopsis
- The study examined how racial, ethnic, and socioeconomic factors affect the use and adherence to novel P2Y12 inhibitors (prasugrel and ticagrelor) among patients with acute coronary syndrome (ACS) from 2008 to 2016.
- Findings showed that Hispanic patients were more likely to be started on clopidogrel instead of novel P2Y12 inhibitors, and wealthier patients (with incomes over $100,000) were less likely to receive clopidogrel than those with lower incomes.
- Overall, the research indicated that non-White races and lower household incomes contributed to lower adherence to P2Y12 inhibitors, emphasizing the need for improved healthcare equity even among insured populations.
Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications.
Curr Atheroscler Rep
November 2017
Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Perelman Center South Tower, 11th Floor 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA.
Purpose Of Review: Platelets are activated upon interaction with injured vascular endothelium to form a primary hemostatic plug. Pathogenic thrombosis driven by platelet aggregation can occur in the setting of vascular disease leading to ischemic events. The use of antiplatelet agents has become a mainstay for prevention of the secondary complications of vascular disease.
View Article and Find Full Text PDF